Stage IIIA Intraocular Melanoma Terminated Phase 2 Trials for Axitinib (DB06626)

IndicationStatusPhase
DBCOND0030838 (Stage IIIA Intraocular Melanoma)Terminated2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01533948Axitinib in Treating Patients With Melanoma That is Metastatic or Cannot Be Removed by SurgeryTreatment